ClinicaliQ Trial Snapshot
- BeSpoke Decision Support for Patients With Newly Diagnosed Localised Prostate Cancer — Recruiting • Non-phase study • Oncology • NCT07135271.
- What is being tested: A personalised decision support intervention (BeSpoke) that provides tailored treatment counselling to help newly diagnosed prostate cancer patients make informed choices between active treatment options (surgery, radiotherapy, active surveillance).
- Patient eligibility overview: Men with newly diagnosed localised prostate cancer who are eligible for multiple treatment modalities and capable of participating in the randomised intervention comparing standard care versus personalised decision support.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this randomised clinical trial is to assess whether personalised treatment counselling can improve the decision-making experience in patients with a new diagnosis of localised prostate cancer. The main question it aims to answer is: • Does the Bespoke Decision Support tool reduce decisional conflict in those choosing between treatment options for localised prostate cancer? Researchers will compare the addition of the Bespoke Decision Support tool to standard treatment counselling versus standard counselling alone. Patient participants will: * Receive standard counselling with or without access to the Bespoke…
Eligibility Snapshot
- for Patient-Participants: 1. Newly diagnosed localised prostate cancer 2. Clinically suitable for at least two of the following treatment options: 1. active surveillance 2. focal therapy 3. radical prostatectomy 4. external beam radiotherapy 3. Willing and able to provide informed consent
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.